Difference between revisions of "Renal neoplasms with TSC/mTOR pathway mutations"
Jump to navigation
Jump to search
(create) |
|||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Renal neoplasms with TSC/mTOR mutations''' is a diverse group of [[kidney tumours]]. | '''Renal neoplasms with TSC/mTOR pathway mutations''' is a diverse group of [[kidney tumours]].<ref>{{cite journal |authors=Kapur P, Brugarolas J, Trpkov K |title=Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting |journal=Cancers (Basel) |volume=15 |issue=16 |pages= |date=August 2023 |pmid=37627070 |pmc=10452688 |doi=10.3390/cancers15164043 |url=}}</ref> | ||
Kidney tumours with TSC/mTOR mutations: | Kidney tumours with TSC/mTOR mutations: | ||
*[[Renal cell carcinoma with fibromyomatous stroma]].<ref name=pmid37899532>{{cite journal |authors=Shah RB, Mehra R |title=Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up |journal=Adv Anat Pathol |volume=31 |issue=2 |pages=105–117 |date=March 2024 |pmid=37899532 |doi=10.1097/PAP.0000000000000419 |url=}}</ref> | |||
*[[Eosinophilic solid and cystic renal cell carcinoma]].<ref name=pmid35203531>{{cite journal |authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O |title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background |journal=Biomedicines |volume=10 |issue=2 |pages= |date=January 2022 |pmid=35203531 |pmc=8869370 |doi=10.3390/biomedicines10020322 |url=}}</ref> | *[[Eosinophilic solid and cystic renal cell carcinoma]].<ref name=pmid35203531>{{cite journal |authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O |title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background |journal=Biomedicines |volume=10 |issue=2 |pages= |date=January 2022 |pmid=35203531 |pmc=8869370 |doi=10.3390/biomedicines10020322 |url=}}</ref> | ||
*[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/> | *[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/> | ||
*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/> | *[[Low-grade oncocytic tumour]].<ref name=pmid35203531/> | ||
Mnemonic: ''REEL''. | |||
==See also== | |||
*[[Everolimus]]. | |||
==References== | ==References== | ||
Latest revision as of 04:28, 20 March 2024
Renal neoplasms with TSC/mTOR pathway mutations is a diverse group of kidney tumours.[1]
Kidney tumours with TSC/mTOR mutations:
- Renal cell carcinoma with fibromyomatous stroma.[2]
- Eosinophilic solid and cystic renal cell carcinoma.[3]
- Eosinophilic vacuolated tumour.[3]
- Low-grade oncocytic tumour.[3]
Mnemonic: REEL.
See also
References
- ↑ Kapur P, Brugarolas J, Trpkov K (August 2023). "Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting". Cancers (Basel) 15 (16). doi:10.3390/cancers15164043. PMC 10452688. PMID 37627070. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452688/.
- ↑ Shah RB, Mehra R (March 2024). "Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up". Adv Anat Pathol 31 (2): 105–117. doi:10.1097/PAP.0000000000000419. PMID 37899532.
- ↑ 3.0 3.1 3.2 Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O (January 2022). "TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background". Biomedicines 10 (2). doi:10.3390/biomedicines10020322. PMC 8869370. PMID 35203531. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869370/.